Skip to main content

Table 2 Random-effects pooled results: duloxetine vs. placebo.

From: Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain

Outcome Treatment effect (θ) 95% CI for θ U-test
(p-value)
τ 2 NNT/NNH
(95% CI)
Efficacy      
Reduction in 24-hour pain intensity -1.128 (-1.364; -0.891) <0.001 0 -
Response 0.856 (0.628; 1.085) <0.001 0 5(3;7)
PGI -0.756 (-1.004; -0.508) <0.001 0 -
Tolerability      
Premature study discontinuation due to:      
- Lack of efficacy -0.962 (-1.800; -0.124) (0.024) 0  
- Adverse events 1.077 (0.663; 1.490) <0.001 0 11 (7; 23)
- Other -0.278 (-0.636; 0.079) (0.127) 0  
Diarrhoea 0.233 (-0.436; 0.903) (0.307) 0.307  
Dizziness 0.817 (0.398; 1.235) <0.001 0  
Headache 0.468 (0.090; 0.845) (0.015) 0  
Nausea 1.306 (0.942; 1.669) 0.039 0.039  
Somnolence 1.472 (1.044; 1.900) <0.001 0  
  1. Note:
  2. θ is absolute difference for 24-hour pain intensity.
  3. θ is log-odds ratio for Response, PGI and all tolerability analyses.
  4. τ 2 is between-study heterogeneity.
  5. NNT/NNH: Number needed to treat, number needed to harm. NNTs were calculated for response rate and NNHs were calculated for discontinuation due to adverse events.